Literature DB >> 27568731

Understanding Tumor-Antigen Presentation in the New Era of Cancer Immunotherapy.

Daniela Cerezo-Wallis, Maria S Soengas1.   

Abstract

For more than a century, scientists have tried to exploit the anti-tumoral potential of the immune system to treat cancer. However, clinical success was traditionally limited. Consequently, classical anti-neoplastic treatments such as surgery, radiotherapy, and chemotherapy used to be the first line of treatment. Fortunately, this scenario is changing, particularly with the identification of immune checkpoint inhibitors. Now more than ever, it becomes essential to understand how cancer cells modulate the immune system. In this review, we summarize main mechanisms of antigen presentation in the tumor microenvironment, a main event in the establishment of anti-tumor immunity. Specifically, we focus on recent progress in mechanisms involved in tumor antigen presentation, as well as on strategies cancer cells develop to favor immune suppressive and immune tolerant enironments. In addition, we briefly discuss current therapeutic approaches to overcome tumor immune evasion. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  Antigen presenting cells; cancer; immunosupression; immunotherapy; immunotolerance; neoantigens

Mesh:

Substances:

Year:  2016        PMID: 27568731     DOI: 10.2174/1381612822666160826111041

Source DB:  PubMed          Journal:  Curr Pharm Des        ISSN: 1381-6128            Impact factor:   3.116


  7 in total

1.  Lipid Metabolism and Tumor Antigen Presentation.

Authors:  Hong Qin; Yaxi Chen
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Melanoma-specific antigen-associated antitumor antibody reactivity as an immune-related biomarker for targeted immunotherapies.

Authors:  Annika Rähni; Mariliis Jaago; Helle Sadam; Nadežda Pupina; Arno Pihlak; Jürgen Tuvikene; Margus Annuk; Andrus Mägi; Tõnis Timmusk; Amir M Ghaemmaghami; Kaia Palm
Journal:  Commun Med (Lond)       Date:  2022-05-11

3.  Complement C3-dependent uptake of targeted liposomes into human macrophages, B cells, dendritic cells, neutrophils, and MDSCs.

Authors:  Alexandra Francian; Kristine Mann; Max Kullberg
Journal:  Int J Nanomedicine       Date:  2017-07-19

4.  Network Pharmacology to Unveil the Biological Basis of Health-Strengthening Herbal Medicine in Cancer Treatment.

Authors:  Jiahui Zheng; Min Wu; Haiyan Wang; Shasha Li; Xin Wang; Yan Li; Dong Wang; Shao Li
Journal:  Cancers (Basel)       Date:  2018-11-21       Impact factor: 6.639

5.  Development of a prognostic signature for esophageal cancer based on nine immune related genes.

Authors:  Zhi Zhang; Cheng Chen; Ying Fang; Sheng Li; Xiaohua Wang; Lei Sun; Guoren Zhou; Jinjun Ye
Journal:  BMC Cancer       Date:  2021-02-04       Impact factor: 4.430

6.  Aggresome-Autophagy Associated Gene HDAC6 Is a Potential Biomarker in Pan-Cancer, Especially in Colon Adenocarcinoma.

Authors:  Zhiyong Zhang; Xin Zhang; Aimin Huang
Journal:  Front Oncol       Date:  2021-08-17       Impact factor: 6.244

Review 7.  Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade.

Authors:  Yu-Chen Chuang; Jen-Chih Tseng; Li-Rung Huang; Chun-Ming Huang; Chi-Ying F Huang; Tsung-Hsien Chuang
Journal:  Front Immunol       Date:  2020-05-29       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.